Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 1 day agoScore90
Body · original
FourLight-1 #ESMO26
In HR+/HER2− advanced #BreastCancer after CDK4/6i progression,atirmociclib + fulvestrant improved median PFS to 9.4 vs 6.6 months (HR 0.60; p=0.0007)
Promising results,but phase 3 validation is needed to establish its role in clinical practice.
@OncoAlert
276 views · 14 likes · 8 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Aya Mohamed | MSc, MD 🎗 · x.com